Options Traders Pick Sides on Centessa as Lilly’s $38 Bid Turns Binary

The catalyst is now live. On Tuesday, Eli Lilly announced a definitive agreement to acquire Centessa Pharmaceuticals in a deal worth about $6.3 billion. The offer is straightforward: $38 per share, representing a roughly 41% premium to Centessa's recent average trading price. But the real intrigue lies in the contingent value right (CVR) structure. Lilly will pay up to an additional $9 per share via a CVR tied to FDA approvals for either of Centessa's two OX2R drugs in narcolepsy or related disorders, adding another potential $1.5 billion to the total value.

The market's reaction was immediate and decisive. Centessa's shares surged 44.4% on the news, with options volume 11 times the average for the session. This isn't passive buying; it's aggressive trader positioning, with calls and puts both heavily active. The setup is clear: a massive, cash-rich acquirer is paying a steep premium for a clinical-stage pipeline, creating a binary event with a defined timeline.

This deal is a strategic pivot for Lilly. It directly addresses a blind spot in Lilly's neuroscience research-sleep disorders-and injects the company into the high-stakes race for OX2R agonists. Centessa's lead candidate, cleminorexton, is being positioned as a potential best-in-class therapeutic for excessive daytime sleepiness. By acquiring Centessa, Lilly isn't just buying drugs; it's acquiring a shot at a next-generation class of medicines for a market analysts describe as "nearly commercial, multi-billion dollar." The catalyst is the deal itself, with its clear price and its high-stakes, FDA-dependent upside.

Options Strategy: Calls, Puts, and the Path to $38

The options activity tells a clear tactical story. Traders are positioning for a volatile outcome right around the $38 offer price. The most active strike is the April 30 call, which gives the holder the right to buy shares at $38 before the end of this month. This is a classic bet on the deal closing smoothly and the stock holding firm near the offer. Simultaneously, the December 22.50 puts are seeing heavy action, suggesting some players are hedging against a potential collapse if the deal falters or if the market overreacts.

This mix of calls and puts at the $38 level indicates a market split. On one side, the options market is betting the deal closes, with the April calls implying a near-term rally to the offer price. On the other, the December puts show a deep skepticism about Centessa's standalone value, with a strike price nearly 40% below the current price. This disconnect is reinforced by the analyst community. Following the announcement, firms like Needham and B. Riley downgraded the stock to "hold" and "neutral," respectively, from "buy." This shift from near-unanimous bullishness to cautious neutrality highlights the fundamental question: is the $38 price a fair premium for a clinical-stage company, or is it a speculative bet on future FDA approvals?

The key near-term catalyst is the deal's closure. The path is supported by a committed stake: entities affiliated with Medicxi Ventures, Index Ventures, and General Atlantic have signed agreements to vote for the deal, representing approximately 24.1% of Centessa's outstanding shares. This provides a base of support, but the final vote is still weeks away. For options traders, the setup is binary. The April 30 call offers a low-cost bet on a smooth close, while the December puts provide a hedge against the high-stakes, FDA-dependent CVR upside that remains uncertain.

The Tactical Setup: Timing, Risk, and the Mispricing

The immediate risk/reward for options traders is defined by a clear mispricing and a binary timeline. The stock's 44.4% surge to over $39 has priced in the deal's $38 offer, creating a tactical opportunity for those who believe the deal will close at that price. The setup is straightforward: if the deal proceeds as announced, the stock should revert toward the offer price, capturing the initial premium. The primary risk is deal failure or significant delay, which would likely cause the shares to collapse back toward pre-announcement levels, erasing the pop.

The contingent value right (CVR) adds a high-stakes, binary upside. Lilly will pay up to an additional $9 per share via the CVR, contingent on FDA approvals for either of Centessa's two OX2R drugs in narcolepsy or related disorders. This could add another potential $1.5 billion to the total deal value. But this is a future event, not a current asset. For now, the CVR is a speculative bet on distant regulatory outcomes, not a near-term catalyst for the stock's current price.

The timing is critical. The deal is expected to close in the third quarter, with the key near-term catalyst being the shareholder vote. Entities affiliated with Medicxi Ventures, Index Ventures, and General Atlantic have signed agreements to vote for the deal, representing approximately 24.1% of Centessa's outstanding shares. This provides a base of support, but the final vote is still weeks away. Traders must weigh the near-term volatility of the vote against the longer-term, uncertain CVR payoff.

For options, the path is clear. The April 30 call at $38 is the primary bet on a smooth close. The heavy activity in December puts at $22.50, however, shows traders are hedging against the deal's failure, which would leave the stock with no premium and only the speculative CVR. The tactical play hinges on the deal's closure. If it fails, the stock's 44% pop is a costly mispricing. If it succeeds, the $38 offer is the new floor. The risk/reward is binary, and the clock is ticking toward the shareholder vote.